Thalassemia Patients and Friends

Discussion Forums => Iron Chelation Corner => Topic started by: ironjustice on June 22, 2010, 01:50:06 PM

Title: FBS0701 orphan drug status
Post by: ironjustice on June 22, 2010, 01:50:06 PM

Scrip    FerroKin secures $12 million for iron overload programme
Today
Peter Mansell

peter.mansell@talk21.com

US biotechnology company FerroKin BioSciences can step up development of its iron overload treatment, FBS0701, after securing additional funds through a $12 million financing.

FBS0701 is an orally available iron chelator that has orphan drug status for the treatment of transfusional iron overload

Title: Re: FBS0701 orphan drug status
Post by: Dori on June 22, 2010, 03:27:11 PM

Aha :)

A few years ago there was about to come a new med on the market of tests with patients (not Exjade) but suddenly it was called back. You can wonder about wether or not this is it, but I think there are more farma's doing research into this.
I am glad you found it!